Molecular Fingerprinting for Cancer Detection

Blood tests based on molecular fingerprinting technology have correctly identified the presence of cancer in each of 206 patients known to have lung, breast, gastrointestinal, or prostate cancer, showing 100% sensitivity. The tests also correctly ruled out cancer in all of the 72 control patients (100% specificity).

Antibodies produced to fight cancer cells reflect the molecular signature, or fingerprint, of a tumor and are generated in cancer's earliest stages, even when the cancer is a collection of single cells. The molecular fingerprinting technology of CeMines, Inc. (Evergreen, CO, USA) detects these antibodies in the blood to precisely diagnose a variety of tumors months or years before conventional methods.

CeMines is building a large database of cancer patients that includes each patient's specific molecular profile, the treatment administered, and the result. By comparing the molecular profile to CeMines database, doctors will know how that specific cancer has responded to a given treatment in the past, and will have better information to make treatment recommendations. Many experimental drugs for cancer have not been approved because it has not been possible to predict which patient will respond positively. Thus, CeMines' molecular fingerprinting technology can contribute to the intelligent drug design of more precise cancer drugs.

"This expanded data validate our belief that our molecular fingerprinting technology has the ability to detect cancer in its earliest stages of formation. We look forward to disclosing additional data as it becomes available,” said Baily E. Dotson, CEO of CeMines.




Related Links:
CeMines